Vanucizumab

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameVanucizumab
Drug Alias Namevanucizumabum伐努赛珠单抗伐诺组单抗RG-7221RO-5520985 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionVascular endothelial growth factor A inhibitorsAngiopoietin-2 inhibitors
TargetsAngiopoietin-2Vascular endothelial growth factor A
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[16] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsColorectal NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia